Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascentage Granted US Rare Pediatric Disease Status for Neuroblastoma Therapy

publication date: Mar 22, 2022

Suzhou Ascentage Pharma announced its novel MDM2-p53 inhibitor was granted US Rare Pediatric Disease to treat neuroblastoma. Alrizomadlin is an oral small-molecule inhibitor of the MDM2 protein that is designed to activate p53 tumor suppression by blocking MDM2-p53 protein-protein interaction. Neuroblastoma, the most common extracranial solid tumor in children and the third most common pediatric cancer, often has a poor prognosis. So far, alrizomadlin has received six Orphan Drug Designations and two RPDs from the FDA. Ascentage is testing alrizomadlin in a Phase II trial to treat immunotherapy-resistant advanced solid tumor cancers. More details....

Stock Symbol: (HK: 6855)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.